we are a commercial-stage, biotechnology organization located in the hot biotech locations of seattle, washington and south san francisco, ca. our world class scientists have invented a patent-pending technology that combines advances in high-throughput sequencing with state-of-the-art computer infrastructure to provide an in-depth analysis of the t- and b-cell repertoire, a specific and important part of the immune system. this information is driving the r&d community to support the fights against cancer, auto-immune disease, and much, much more. we're often asked to describe our company culture. it is very easy ... we're a hard working group of top-notch individuals who are passionate about wanting to make a difference in the world. we know our employees are our most valuable asset, and every employee’s contribution is appreciated. open communication and collaboration are always encouraged in every interaction throughout the organization. we have high expectations of ourselves, and
Company profile
Ticker
ADPT
Exchange
Website
CEO
Chad Robins
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
Former names
Adaptive TCR Corp
SEC CIK
Corporate docs
Subsidiaries
Digital Biotechnologies, Inc. • Adaptive Biotechnologies B.V. ...
IRS number
270907024
ADPT stock data
Latest filings (excl ownership)
8-K
Departure of Directors or Certain Officers
9 Apr 24
8-K
Adaptive Biotechnologies Provides Strategic Review Update and Announces Preliminary First Quarter 2024 Revenue
5 Apr 24
8-K
Departure of Directors or Certain Officers
2 Apr 24
10-K
2023 FY
Annual report
29 Feb 24
8-K
Adaptive Biotechnologies Reports Fourth Quarter and Full Year 2023 Financial Results
14 Feb 24
10-Q
2023 Q3
Quarterly report
9 Nov 23
8-K
Adaptive Biotechnologies Reports Third Quarter 2023 Financial Results and Provides Business Update
9 Nov 23
8-K
Departure of Directors or Certain Officers
1 Sep 23
10-Q
2023 Q2
Quarterly report
2 Aug 23
8-K
Adaptive Biotechnologies Reports Second Quarter 2023 Financial Results
2 Aug 23
Transcripts
ADPT
Earnings call transcript
2023 Q4
14 Feb 24
ADPT
Earnings call transcript
2023 Q3
9 Nov 23
ADPT
Earnings call transcript
2023 Q2
2 Aug 23
ADPT
Earnings call transcript
2023 Q1
3 May 23
ADPT
Earnings call transcript
2022 Q4
14 Feb 23
ADPT
Earnings call transcript
2022 Q3
4 Nov 22
ADPT
Earnings call transcript
2022 Q2
4 Aug 22
ADPT
Earnings call transcript
2022 Q1
4 May 22
ADPT
Earnings call transcript
2021 Q4
16 Feb 22
ADPT
Earnings call transcript
2021 Q3
4 Nov 21
Financial summary
Quarter (USD) | Sep 23 | Jun 23 | Mar 23 | Dec 22 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) | Dec 22 | Dec 21 | Dec 20 | Dec 19 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
---|---|---|---|---|---|---|
Cash on hand (at last report) | 91.63 mm | 91.63 mm | 91.63 mm | 91.63 mm | 91.63 mm | 91.63 mm |
Cash burn (monthly) | 6.84 mm | 10.70 mm | 16.99 mm | 16.26 mm | 15.56 mm | 13.28 mm |
Cash used (since last report) | 45.62 mm | 71.30 mm | 113.23 mm | 108.41 mm | 103.73 mm | 88.55 mm |
Cash remaining | 46.02 mm | 20.33 mm | -21.59 mm | -16.78 mm | -12.10 mm | 3.08 mm |
Runway (months of cash) | 6.7 | 1.9 | -1.3 | -1.0 | -0.8 | 0.2 |
Institutional ownership, Q3 2023
96.7% owned by funds/institutions
13F holders | Current |
---|---|
Total holders | 185 |
Opened positions | 16 |
Closed positions | 37 |
Increased positions | 58 |
Reduced positions | 73 |
13F shares | Current |
---|---|
Total value | 760.19 bn |
Total shares | 140.29 mm |
Total puts | 32.50 k |
Total calls | 37.70 k |
Total put/call ratio | 0.9 |
Largest owners | Shares | Value |
---|---|---|
Viking Global Investors | 29.99 mm | $163.47 bn |
Vanguard | 12.25 mm | $66.76 bn |
BLK Blackrock | 11.59 mm | $63.14 bn |
Matrix Capital Management | 11.57 mm | $63.07 bn |
ARK Investment Management | 11.51 mm | $62.73 bn |
CMTDF Sumitomo Mitsui Trust | 6.57 mm | $35.81 bn |
Nikko Asset Management Americas | 6.57 mm | $35.68 bn |
Point72 Asset Management | 5.71 mm | $31.14 bn |
Aristotle Atlantic Partners | 3.06 mm | $16.67 bn |
Pictet Asset Management Holding | 3.04 mm | $16.58 bn |
Recent insider trades
Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
---|---|---|---|---|---|---|---|---|---|---|
12 Mar 24 | Peter M Neupert | Common Stock | Option exercise | Acquire M | No | No | 0.84 | 15,000 | 12.60 k | 169,296 |
12 Mar 24 | Peter M Neupert | Stock Option Common Stock | Option exercise | Dispose M | No | No | 0 | 15,000 | 0.00 | 0 |
5 Mar 24 | Susan Bobulsky | Common Stock | Sell | Dispose S | No | No | 3.44 | 6,975 | 23.99 k | 248,290 |
5 Mar 24 | Susan Bobulsky | Common Stock | Sell | Dispose S | No | No | 3.43 | 6,016 | 20.63 k | 255,265 |
5 Mar 24 | Tycho Peterson | Common Stock | Sell | Dispose S | No | No | 3.44 | 15,456 | 53.17 k | 531,553 |
5 Mar 24 | Robins Chad M | Common Stock | Sell | Dispose S | No | No | 3.43 | 42,794 | 146.78 k | 2,576,701 |
5 Mar 24 | Robins Chad M | Common Stock | Sell | Dispose S | No | No | 3.44 | 5,879 | 20.22 k | 2,619,495 |
4 Mar 24 | Susan Bobulsky | Common Stock | Grant | Acquire A | No | No | 0 | 132,979 | 0.00 | 261,281 |
4 Mar 24 | Susan Bobulsky | Stock Option Common Stock | Grant | Acquire A | No | No | 3.99 | 199,549 | 796.20 k | 199,549 |
4 Mar 24 | Tycho Peterson | Common Stock | Grant | Acquire A | No | No | 0 | 147,790 | 0.00 | 547,009 |
News
Why Wang & Lee Group Shares Are Trading Higher By 38%; Here Are 20 Stocks Moving Premarket
19 Apr 24
Why Travelers Shares Are Trading Lower By Around 8%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session
17 Apr 24
BTIG Maintains Buy on Adaptive Biotechnologies, Lowers Price Target to $5
4 Apr 24
Adaptive Biotechnologies Names New CFO Preserves Strong Capital Position
3 Apr 24
Adaptive Biotechnologies Provides Strategic Review Update And Announces Preliminary Q1 2024 Revenue Of $41M-$43M Vs $38.21M Est.
2 Apr 24
Press releases
Adaptive Biotechnologies to Report First Quarter 2024 Financial Results on May 7, 2024
17 Apr 24
Adaptive Biotechnologies Provides Strategic Review Update and Announces Preliminary First Quarter 2024 Revenue
2 Apr 24
Adaptive Biotechnologies to Hold a Business Update Conference Call and Webcast on April 2, 2024
27 Mar 24
Adaptive Biotechnologies to Present at the TD Cowen 44th Annual Healthcare Conference
22 Feb 24
Adaptive Biotechnologies Reports Fourth Quarter and Full Year 2023 Financial Results
14 Feb 24